在研发与生产布局方面，公司重视全球资源整合与产能保障，目前已在全球范围内设立5个研发中心及实验 室，持续推动核心技术迭代与创新产品研发;建立4个生产基地，确保产品规模化、高质量供应;同时搭建3个 国际运营中心，为全球市场拓展提供高效的运营支持与服务保障。 在市场覆盖维度方面，公司产品已成功行销海内外超100个国家和地区，服务于全球上万家医院及医疗中 心，凭借稳定的产品性能、成体系的治疗解决方案及专业的技术支持，在国内外血管介入医疗器械市场树 立了良好的品牌形象，逐步构建起全球化的市场布局与客户服务网络。 公司长期践行"创新+规模化+国际化"三位一体经营发展战略，已成长为全球血管介入产业领域高速发展、 具备重要行业影响力的跨国型平台企业，"助力中国原创、造福全球患者"亦是公司科技创新与全球产业化 的核心发展理念。自创立以来，公司持续保持高强度研发投入，构建完善高效的研发人才团队与IPD产品研 发体系，依托广东省血管介入治疗技术及器械工程技术研究中心、东莞市血管介入医疗器械研究开发重点 实验室、CNAS实验室等核心科研载体，通过全球范围的产学研合作与医工创新合作，在产品技术、核心工 艺等领域取得多项全球性突破。截 ...

Group 1 - The core stock price of Sino Medical reached 33.38 yuan as of August 25, 2025, with an increase of 0.68 yuan, representing a rise of 2.08% [1] - The trading volume on that day was 2.307 billion yuan, with a turnover rate of 16.47% [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of high-end interventional medical devices, including coronary stents and balloon catheters [1] Group 2 - The company's subsidiary, Sino Shenchang Medical Technology Co., Ltd., recently received a registration certificate from the National Medical Products Administration for a disposable microcatheter, which is suitable for neurovascular operations [1] - The registration certificate for the microcatheter is valid until August 21, 2030 [1] - For the first half of 2025, the company reported revenue of 240 million yuan and a net profit attributable to the parent company of 13.84 million yuan [1] Group 3 - On August 25, 2025, the net outflow of main funds was 107 million yuan, with a cumulative net outflow of 1.454 billion yuan over the past five days [2]

Group 1 - The stock price of Sino Medical reached 30.40 yuan as of August 14, 2025, marking a 3.05% increase from the previous trading day [1] - The trading volume on that day was 2.26 billion yuan, with a turnover rate of 18.55% [1] - Sino Medical specializes in the research, production, and sales of cardiovascular interventional medical devices, including coronary stents and balloon catheters [1] Group 2 - A subsidiary of Sino Medical recently received recognition from the U.S. Food and Drug Administration (FDA), which has generated market interest in its potential applications in the field of neurovascular intervention [1] - On August 14, the net inflow of main funds was 164 million yuan, accounting for 1.3% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 143 million yuan [1]

Group 1 - The stock price of Sino Medical reported at 14.19 yuan as of August 6, 2025, down by 2.54% from the previous trading day [1] - The trading volume on that day was 119,538 hands, with a transaction amount of 171 million yuan [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of high-end interventional medical devices, including cardiovascular interventional devices like stents and balloon catheters [1] Group 2 - The company's subsidiary, Sino Shenchang, specializes in the development of products in the neurointerventional field [1] - Sino Shenchang's COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter have received breakthrough medical device designation from the FDA [1] - This product is the first in FDA history for the treatment of intracranial atherosclerotic stenosis and the first domestically produced neurointerventional device to receive such designation [1] Group 3 - On the funding flow side, there was a net outflow of 28.91 million yuan from main funds on that day, accounting for 0.49% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 33.18 million yuan, representing 0.56% of the circulating market value [1]